Belgium’s largest pharma company UCB (Euronext: UCB) this morning posted financial results for the first half of 2022, which it described as “strong,” but investors were not convinced, sending the firm’s shares more than 4% lower to 77.92 euros.
Revenue increased to 2.93 billion euros ($2.97), +5%; +3% constant exchange rates (CER), net sales were 2.70 billion (+2%; 0% CER) – impacted by generic erosion on two leading brands.
Underlying profitability (adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was 814 million euros (-3%; -2% CER), 28% of revenue – impacted by the inclusion since March of Zogenix, which UCB acquired for $1.9 billion. Core earnings per share were down 7% at 3.15 euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze